Abstract Sphingolipids are bioeffector molecules that control various aspects of cell growth, proliferation, apoptosis, and drug resistance. Ceramides, the central molecule of sphingolipid metabolism, are inducer of apoptosis and inhibitors of proliferation. Sphingosine-1-phosphate (S1P) and glucosyleceramide, converted from ceramides by sphingosine kinase-1 (SK-1) and glucosyleceramide synthase (GCS) enzymes, respectively, inhibit apoptosis and develop resistance to chemotherapeutic drugs. In this study, we examined the therapeutic potentials of bioactive sphingolipids in chronic myeloid leukemia (CML) alone and in combination with dasatinib in addition to investigate the roles of ceramide-metabolizing genes in dasatinib-induced apoptosis. Cytotoxic effects of dasatinib, C8:ceramide, PDMP, and SK-1 inhibitor were determined by XTT cell proliferation assay. Changes in caspase-3 enzyme activity and mitochondrial membrane potential (MMP) were measured using caspase-3 colorimetric assay and JC-1 MMP detection kit. Expression levels of ceramide-metabolizing genes were examined by qRT-PCR. Application of ceramide analogs and inhibitors of ceramide clearance genes decreased cell proliferation and induced apoptosis. Targeting bioactive sphingolipids towards generation/accumulation of ceramides increased apoptotic effects of dasatinib, synergistically. It was shown for the first time that dasatinib induces apoptosis through downregulating expression levels of antiapoptotic SK-1 but not GCS, and upregulating expression levels of ceramide synthase (CerS) genes, especially CerS1, in K562 cells. On the other hand, dasatinib downregulates expression levels of both GCS and SK-1 and upregulate apoptotic CerS2, −5 and −6 genes in Meg-01 cells. Increasing endogenous ceramide levels and decreasing prosurvival lipids, S1P, and GC, can open the way of more effective treatment of CML.
Introduction
Chronic myeloid leukemia is a hematopoetic stem cell disorder characterized by the presence of constitutively active breakpoint cluster region (BCR)/Abelson (ABL) oncoprotein [1] . BCR/ABL oncoprotein results from a reciprocal translocation of a section of human chromosome 9 that contains the ABL kinase domain and a specific BCR on chromosome 22 [2, 3] . BCR/ABL oncoprotein regulates many signaling pathways involved in cell growth and proliferation, apoptosis, and differentiation [4] . It was shown by different studies that expression of BCR/ABL alone is enough to interpret chronic myeloid leukemia (CML) [5] [6] [7] . Development and application of imatinib that targets BCR/ABL oncoprotein is an important milestone for the treatment of (CML). Imatinib binds to adenosine triphosphate (ATP)-binding site of BCR/ABL and inhibits phosphorylation of BCR/ABL targets that prevent leuke-mogenesis [8] . But, although very high hematological and cytogenetical responses were obtained in response to imatinib in the beginning, drug resistance was the major drawback in imatinib-based protocols [9] .
Dasatinib, is a multikinase inhibitor that inhibits the activity of BCR/ABL and SRC kinases including SRC, LCK, YES, and FYN in addition to c-KIT and PDGFRalpha and beta [10] . It acts as a competitive inhibitor at the ATP-binding site of BCR/ABL, preventing tyrosine phosphorylation of the substrate molecule and downstream signaling, causing growth arrest and apoptosis [11] . Dasatinib demonstrated significant activity against the mutations on its binding site including the ones causing poor prognosis in imatinib treatment. Dasatinib is used for the treatment of BCR-ABL-positive CML, resistant or intolerant to imatinib patients while it is also approved for Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia patients [12] . Dasatinib also demonstrated antitumoral activities on solid tumors such as prostate, breast, lung or head, and neck cancers [13] [14] [15] [16] .
Bioactive sphingolipids ceramide, sphingosine 1-phophate (S1P), sphingosine, and glucosylceramide (GlcCer) are involved in initiation and progression of cancer. They regulate cell growth, cell proliferation, apoptosis, senescence, and drug resistance [17, 18] . Ceramides are synthesized either de novo by ceramide synthase genes (CerS1-6) or by breakdown of sphingomyelin by sphingomyelinase enzyme [19] . Different length of ceramides were synthesized by different CerS genes [20] . While CerS1 is responsible for synthesis of C18-ceramide [21] , CerS2 and CerS4 increase the levels of C24-ceramides and C22-ceramides, respectively [22, 23] . C14-ceramides and C16-ceramides were sythesised by CerS5 and CerS6 genes [24, 25] . Ceramides act as strong antitumoral molecules supressing cell growth and proliferation and inducing apoptosis and differentiation [26] . On the other hand, GlcCer and S1P molecules converted from ceramide by glucosylceramide synthase (GCS) and sphingosine kinase-1 (SK-1) enzymes act as strong antiapoptotic molecules inducing cell growth and proliferation and inhibiting apoptosis and differentiation [27, 28] . Thus, the balance between ceramide/GlcCer or ceramide/S1P significantly affects the fate of the cell to die or to survive. It was also shown that intracellular concentrations of ceramides are increased in response to stress conditions. But in cancerous tissues and cells and in more agressive resistant cell expressions, levels of GCS and SK-1 increases significantly [26] [27] [28] .
In the present study, we examined the roles of ceramidemetabolizing genes in apoptosis in response to dasatinib in Ph positive (CML) cells. We also tried to increase apoptotic effects of dasatinib on CML cells by targeting bioactive sphingolipids.
Materials and methods

Reagents
Dasatinib was obtained from BMS, USA. A 10-mM stock solution was prepared with DMSO and stored at −20°C. C8:ceramide, N-(2-hydroxy-1-(4-morpholinylmethyl)-2-phenylethyl)-decanamide, hydrochloride (PDMP), and SK-1 inhibitor were obtained from Cayman Chemicals, USA, dissolved in DMSO and stored at −20°C. The final concentration of DMSO did not exceed more than 0.1% in culture. Primers were obtained from Eurofins, Germany.
Cell lines and culture conditions K562 and Meg-01 human CML cells were obtained from the German Collection of Microorganisms and Cell Cultures (Germany). The cells were cultured in RPMI-1640 growth medium containing 10% fetal bovine serum and 1% penicillin-streptomycin (Invitrogen, USA) at 37°C in 5% CO 2 .
Measurement of cell growth by XTT
Antiproliferative effects of dasatinib, C8:ceramide, SK-1 inhibitor, and PDMP were determined by XTT cell proliferation assay as described previously [29] . Briefly, 96-well plates were seeded with 2×10 4 cells/well containing 200 μl of the growth medium in the absence or presence of increasing concentrations of the agents. The cells were incubated at 37°C in 5% CO 2 for 72 h. Then, they were treated with 40-μl XTT for 4 h at CO 2 incubator. After that, the plates were read at 490 nm by Elisa reader (Thermo Electron Corporation Multiskan Spectrum, Finland). Finally, IC50 values of dasatinib and C8:ceramide, and IC10 values of PDMP and SK-1 inhibitor were calculated from cell proliferation plots. We combined increasing concentrations of dasatinib with IC10 values of PDMP and SK-1 inhibitor since we have previously shown that IC10 values of these chemicals are enough to inhibit the enzyme activities and provide accumulation of ceramides in the cells [9] . In parallel experiments, we combined IC50 value of C8: ceramide with increasing concentrations of dasatinib since ceramide analogs trigger induction of generation of apoptotic ceramides at IC50 value [30] . The magic behind these experiments was to determine possible synergistic antiproliferative effects dasatinib on K562 and Meg-01 cells in which intracellular ceramide concentrations were increased.
Isobologram analysis for median dose effect
We used the CalcuSyn for Windows computer program (CalcuSyn software, Biosoft, Cambridge, UK) for isobologram analysis [31] . We studied the isobologram analysis of dasatinib with C8:ceramide, PDMP, and SK-1 inhibitor using the computer software. Experimental data points represented by dots located below, on, or above the line, indicate synergism, additivity, and antagonism, respectively. The CI is an analysis of the combined effects of two drugs using a median effect plot analysis. A CI value <1 indicates a synergistic effect (0.1-0.5 strong synergism; <0.1 very strong synergism); a CI value of 1 indicates additive effect; and a CI value >1 an antagonistic effect (3.3-10 strong antagonism; >10 very strong antagonism).
Measurement of changes in caspase-3 enzyme activity
Changes in caspase-3 enzyme activity in response to applied anyone of these chemical agents were assessed by caspase-3 colorimetric assay kit (R&D Systems, USA) as described previously [32] . The cells were treated with C8: ceramide, PDMP, or SK-1 inhibitor itself and in combination with dasatinib for 72 h. Untreated cells were used as control group. The cells were collected by centrifugation at 1,000 rpm for 10 min, and treated with 100 μl of cold lysis buffer (1X) to obtain cell lysate. After incubating the cell lysates on ice for 10 min, they were centrifuged at 14,000 rpm for 1 min. Then, the supernatants were transferred to new microcentrifuge tubes. In order to measure caspase-3 enzyme activity, reaction mixture including 20 μl of assay buffer (5X), 25 μl of sample, 50 μl of sterilized water, and 5 μl of caspase-3 colorimetric substrate was prepared in 96-well plates and incubated for 2 h at 37°C. The samples were read under 405 nm wavelengths by Elisa reader (Thermo Electron Corporation Multiskan Spectrum, Finland). After measuring protein concentrations by Bradford assay, enzyme activity levels were normalized to protein concentrations.
Detection of the loss of mitochondrial membrane potential (MMP)
APO LOGIX JC-1 Assay Kit (Cell Technology, USA) was used to measure the changes in mitochondrial membrane potential in K562 and Meg-01 cells as described previously [32] . Shortly, the cells that had been induced to apoptosis were collected by centrifugation at 1,000 rpm for 10 min. Supernatants were removed, and 500 μl of JC-1 dye (1%) was added onto the pellets. After incubation of cells for 15 min at 37°C in 5% CO 2 , they were centrifuged at 1,000 rpm for 5 min. Then, 2 ml of assay buffer was added onto the pellets, and they were centrifuged for 5 min at 1,000 rpm. All the pellets were resuspended with 500 μl assay buffer, and 150 μl from each of them was added into black 96-well plate for a triplet measurement. The aggregate red form has absorption/emission maxima of 585/ 590 nm, and the green monomeric form has absorption/ emission maxima of 510/527 nm. The plate was read in Total RNA isolation and quantitative reverse transcriptase-PCR The involvement of CerS1-6 and ceramide clearance genes (SK-1 and GCS) in dasatinib-induced apoptosis was investigated by examining the expression levels of these genes in response to dasatinib in K562 and Meg-01 cells. To achieve this aim, the cells were incubated in the absence and presence of increasing concentrations of dasatinib, and total cellular RNAs were isolated by using RNA Isolation Kit (Macherey-Nagel, USA). The amount and quality of RNAs were measured by Nanodrop Photospectrometer (NanoDrop 1000 THERMO, USA). The mRNAs from total RNA population were reverse transcribed into cDNA by using reverse transcriptase enzyme (Moroney Murine Leukemia Virus Reverse Transcriptase, Fermentas, USA). After 50 min incubation at 42°C, the reactions were stopped at 95°C for 5 min. The resulting total cDNA was used in qPCR to measure the mRNA levels of CerS1-6, SK-1, and GCS using Roche LightCycler® 480 Real-Time PCR System (Roche, USA). The mRNA levels of β actin were used as internal positive control. The primer sequences were as follows:
and β-actin-F (5′-CAGAGCAAGAGAGGCATCCT-3′); and β-actin-R (5′-TTGAAGGTCTCAAACATGAT-3′).
Results
C8:ceramide, PDMP, and SK-1 inhibitor decreased proliferation of CML cells in a dose-dependent manner
We have previously determined antiproliferative effects of C8:ceramide (IC50; 60 μM), PDMP (IC10; 20 μM), and SK-1 inhibitor (IC10; 7 μM) on K562 cells [33] . Increasing intracellular generation and accumulation of ceramides decreased proliferation of Meg-01 cells. IC50 value of C8:ceramide was calculated and found to be 70 μM (Fig. 1a) and IC10 values of PDMP and SK-1 inhibitor were calculated as 50 μM (Fig. 1b) and 5 μM (Fig. 1c) for Meg-01 cells, respectively. Dasatinib/C8:ceramide, /PDMP, and /SK-1 inhibitor inhibited proliferation of CML synergistically
The possible synergistic antiproliferative effects of combination of dasatinib with the ceramide analog and inhibitor of ceramide clearance enzymes were determined by XTT assay. IC50 concentration of C8:ceramide and IC10 concentrations of PDMP and SK-1 inhibitor were applied to K562 and Meg-01 cells in combination with increasing concentrations of dasatinib for 72 h. IC50 concentrations of C8:ceramide were chosen based on its inhibitory effects on proliferation while IC10 values of PDMP and SK-1 inhibitor were preferred because at these concentrations they only inhibit enzyme activity but has no effect on cells were determined by the XTT cell proliferation assay. The XTT assays were performed using triplicate samples in at least three independent experiments. The error bars represent the standard deviation. Statistical significance was determined using one-way analysis of variance, and p<0.05 was considered to be significant proliferation. CML cells were treated with different concentrations of dasatinib (0.01 to 100 nM) for 72 h to determine the effects on cell proliferation. IC50 of dasatinib was found as 4 and 55 nM for K562 and Meg-01 cells, respectively (Fig. 2a, b ).
There were 26% and 31% decreases in cell proliferation compared to untreated controls in response to 0.1 and 1 nM dasatinib in K562 cells (Fig. 2a) . But combinations of the same doses of dasatinib with IC50 concentration of C8: ceramide decreased proliferation of K562 cells by 72% and 76%, with IC10 value of PDMP of 42% and 49%, and with IC10 value of SK-1 inhibitor of 40% and 45% as compared to control, respectively (Fig. 2a) . Similar set of experiment was performed for Meg-01 cells. The results also demonstrated that there were synergistic antiproliferative effects of increasing concentrations of dasatinib (1-500 nM) with C8:ceramide, PDMP, and SK-1 inhibitor as compared to any agent alone and to untreated control group (Fig. 2b) .
As shown in Fig. 3a , the CI values of dasatinib in combination with C8:ceramide, PDMP, and SK-1 inhibitor were 0.00160, 0.26330, and 0.26330, respectively, in K562 cells. Combinations of dasatinib with C8:ceramide, PDMP, and SK-1 inhibitor gave the CI values of 0.00258, 0.00253, and 0.23522, respectively, in Meg-01 cells (Fig. 3b) . A CI value <1 indicates a synergistic effect (0.1-0.5 strong The synergistic apoptotic effects of increased ceramide levels in combination with dasatinib In order to determine the possible synergistic apoptotic effects of elevated ceramide levels in dasatinib-induced apoptosis, K562 and Meg-01 cells were pretreated with C8:ceramide, PDMP, and SK-1 inhibitor. The combinational effects of dasatinib with C8:ceramide, PDMP, and SK-1 inhibitor were examined by the loss of mitochondrial membrane potential (Fig. 4a, b) and increases in caspase-3 enzyme activity (Fig. 5a, b) . The results showed that increasing intracellular concentrations of ceramides by any one of these agents or dasatinib application resulted in loss of MMP and increased caspase-3 enzyme activity in a dose-dependent manner compared to untreated controls to a certain extent. However, application of dasatinib in K562 and Meg-01 cells, pretreated with short-chain ceramides and inhibitors of ceramide clearance enzyme, caused significant loss of MMP and increases in caspase-3 enzyme activity in both K562 On the other hand, the most significant increases were observed in combination of dasatinib with C8:ceramide as compared to others indicating that ceramide generation may be a more effective treatment way than inhibition of ceramide clearance.
The involvement of ceramide-metabolizing genes in dasatinib-induced apoptosis
In order to examine the role of ceramide generation and ceramide clearance genes in dasatinib-induced apoptosis, K562 and Meg-01 cells were exposed to increasing concentrations of dasatinib. Since Meg-01 cells are less sensitive to dasatinib, they were exposed to higher concentrations of dasatinib than K562 cells. qRT-PCR data showed that there were significant increases in expression levels of CerS1 (350% and 530%), CerS2 (250% and 271%), CerS4 (101% and 101%), CerS5 (160% and 190%), and CerS6 (124% and 150%) in K562 cells exposed to 0.1 and 1 nM dasatinib, respectively (Fig. 6a) , while expression levels of SK-1 decreased significantly (26%). Interestingly, expression levels of GCS was increased in response to dasatinib. That may result from significant generation of ceramides.
On the other hand, 10 nM dasatinib application resulted in 40% and 84% decreases in expression levels of antiapoptotic GCS and SK-1 genes in Meg-01 cells, respectively (Fig. 6b ). There were 275%, 129%, and 168% increases in mRNA levels of apoptotic CerS2, Cers5, and CerS6 genes in response to 10 nM dasatinib in Meg-01 cells while expression levels of CerS1 and CerS4 decreased Fig. 4 Percent changes in cytoplasmic/mitochondrial JC-1 in CML cells treated with combinations of dasatinib with C8: ceramide, PDMP, and SK-1 inhibitor. The results are the means of three independent experiments. The error bars represent the standard deviations, and when not seen, they are smaller than the thickness of the lines on the graphs. Statistical significance was determined using two-way analysis of variance, and p<0.05 was considered to be significant slightly as compared to untreated controls and normilized to beta-actin levels (Fig. 6b) .
Discussion
Dasatinib is the second generation tyrosine kinase inhibitor that can bind both inactive and active forms of BCR/ABL [34] . Despite the fact that dasatinib is much more effective than imatinib for the treatment of CML, resistance to dasatinib is still the major drawback in CML treatment [35] . Therefore, increasing the sensitivity of CML cells to dasatinib can provide an important outcome.
Alterations in metabolism of bioactive sphingolipids are important regulators of tumor initiation, progression, and chemoresistance. The balance between proapoptotic and prosurvival signaling is affected by the ratio between ceramide and sphingosine-1-phosphate or glucosylceramide. Specific types of cancers can escape from cell death by converting ceramide to sphingosine-1-phosphate or to glucosyle ceramide by SK-1 and GCS enzymes, respectively [36] . Therefore, targeting ceramide-metabolizing genes alone and in combination with anticancer agents may be an attractive treatment modality for various types of cancers. In the current study, we tried to increase apoptotic effects of dasatinib in combination with ceramide analogs and inhibitors of ceramide clearance enzymes.
It is very well-known that both exogenously applied C8-ceramide, PDMP, and SK-1 inhibitors elevate endogenous ceramide concentrations in various types of cancers [9, 30] . In this study, we documented that inhibition of GCS and SK-1 with specific chemical inhibitors and exogenous C8:ceramide application inhibited cell proliferation and induced apoptosis in a dose-dependent manner in both K562 and Meg-01 CML cells. We also treated K562 and Meg-01 cells with combination of dasatinib and PDMP or SK-1 inhibitor or C8:ceramide. All combinations induced apoptosis significantly as compared to any agent alone but the most Fig. 5 Percent changes in caspase-3 enzyme activity in response to coadministration of dasatinib with C8:ceramide, PDMP, and SK-1 inhibitor. The results are the means of three independent experiments. The error bars represent the standard deviations, and when not seen, they are smaller than the thickness of the lines on the graphs. Statistical significance was determined using two-way analysis of variance, and p<0.05 was considered to be significant significant increase in apoptosis was observed in combination of dasatinib and C8:ceramide. It was also shown previously by our group and Senkal et al. that exogenous ceramide analog applications increased apoptotic effects of different anticancer agents in various types of cancers [37, 38] .
Glucosyl ceramide synthase is the enzyme that transfers glucose to ceramide. Gouaze et al. have shown that inhibition of GCS increases sensitivity of resistant breast cancer cells to chemotherapy [39] . It was also shown that there is a direct relation between GCS and drug resistance. They introduced GCS gene into sensitive MCF-7 breast cancer cells and observed an apparently increase in the GCS expression levels and as a result, the cells became adriamycin and exogeneous ceramides resistant [40] .
Targeting sphingosine kinase-1 is a novel approach for the treatment of cancers. S1P is involved in tumor growth, proliferation, metastasis, and angiogenesis. Overexpression of SK-1 was observed in various types of tumors including lung, intestine, kidney, breast, and ovary tumor as compared to their normal counterpart tissues [41, 42] . SK-1 inhibitor, safingol, alone demonstrated antiproliferative effects on gastric, breast, neuroblastoma, lung, melanoma, prostate, colon, and pancreas cancers [43, 44] . Schwartz et al. demonstrated that safingol increased apoptotic effects of mitomycin-C synergistically in gastric cancer cells.
The antiproliferative and apoptotic effects of exogenous ceramides has been demonstrated in different human cancer cells [37, 38] . Struckhoff et al. have shown apoptotic effects of ceramide analogs on breast cancer cells while some other structural ceramide analogs also showed antiproliferative effects on adriamycin-resistant SKBr3 and MCF-7 human breast cancer cells [45, 46] .
On the other hand, dasatinib has anticancer effects not only on CML but also on BCR/ABL negative tumors including chronic lymphoid leukemia, acute myeloid leukemia, prostate, lung, and non-small lung cancers [47] [48] [49] [50] . In addition to inhibition of BCR/ABL, dasatinib can also target SRC family kinases, Lyn kinase, and EGFR [47] [48] [49] [50] . In order to understand the mechanisms of dasatinib-induced apoptosis, we examined the expression patterns of ceramide-metabolizing genes in CML cells exposed to dasatinib. The qRT-PCR results revealed that there were significant increases in expression levels of CerS1, CerS2, CerS5, and CerS6 genes in response to dasatinib in K562 cells in a dose-dependent manner, while SK-1 is downregulated and slight increases were observed in expression pattern of GCS as compared to untreated Fig. 6 Expression levels of ceramide generation and ceramide clearence genes in response to dasatinib K562 and Meg-01 cells. 0.1 and 1 nM dasatinib were applied to K562 cells while Meg-01 were exposed to 10 nM dasatinib for 72 h and expression levels of ceramidemetabolizing genes were determined by qRT-PCR. Expression levels of beta actin were detected as internal positive controls controls. On the other hand, there were upregulations of CerS2, CerS5, and CerS6 genes and downregulation in SK1 and GCS in response to dasatinib in Meg-01 cells. The results of qRT-PCR analyses may explain the sensitivity of K562 cells to dasatinib as compared to Meg-01 cells. While IC50 value of dasatinib in K562 cells was 4 nM, it was 55 nM for Meg-01 cells. While dasatinib downregulates expression levels of SK-1 and its application results in significant increases in expression levels of all CerS genes that result in increased generation and accumulation of apoptotic ceramides in K562 cells (Fig. 6a) . However, in Meg-01 cells, since dasatinib application results in slight increases and even decreases in expression levels of ceramide-generating genes (Fig. 6b) . On the other hand, there may be some other unknown mechanisms of dasatinib-induced apoptosis regulated differently in K562 and Meg-01 cells that results in differences in their sensitivity to dasatinib.
As a conclusion, in agreement with each other, our data demonstrated increasing intracellular concentrations of ceramides by targeting bioactive sphingolipids increased apoptotic effects of dasatinib synergistically. This approach being supported by clinical data may provide more effective treatment of CML patients.
